B420 Clinical Trial Deep Dive: What It Shows and What It Does Not Prove

Most weight-management summaries of Bifidobacterium animalis subsp. lactis 420, better known as B420, repeat the same headline figures: a four percent reduction in body fat, roughly an inch off the waistline, and about 300 fewer calories eaten per day. Nearly all of those figures trace back to a single published trial: Stenman and colleagues, EBioMedicine, 2016.

That is one of the more meaningful data points behind any probiotic strain marketed for weight, and it is also a study that gets summarized in very different ways depending on who is doing the summarizing. Marketing tends to pick the strongest numbers. Skeptics point out the caveats. Neither is wrong, and neither is complete on its own.

This plain-English review explains what the trial did, what its results show, and what it does not establish. The same distinctions guide how WonderBiotics describes B420 in its Probiotics for Weight Management formula.

The Short Answer

The Stenman 2016 trial is a well-designed, six-month randomized controlled trial that produced consistent signals for reduced abdominal fat, smaller waist size, and lower daily calorie intake in participants who took B420 with dietary fiber and followed the protocol. Its pre-specified primary analysis was not statistically significant, however, and the widely quoted numbers come from a per-protocol subset and a post-hoc factorial analysis, not the primary comparison. No fully independent trial has yet replicated those findings. WonderBiotics therefore includes B420 in Probiotics for Weight Management at the studied dose while describing the evidence as strain-level and specific to the population that was actually studied.

How the Trial Was Designed

The trial was a double-blind, randomized, placebo-controlled study conducted at four clinical research centers in southern Finland between December 2013 and May 2015. It was funded by DuPont Nutrition & Health, the company that developed B420, and most authors were DuPont employees at the time. The full protocol is registered at ClinicalTrials.gov as NCT01978691.¹

Two hundred twenty-five participants were randomized in equal proportions to four arms:

• Placebo: 12 g/day of microcrystalline cellulose in a smoothie sachet
• LU: 12 g/day of Litesse Ultra polydextrose, a soluble dietary fiber
• B420: 10¹⁰ colony-forming units per day of B. animalis subsp. lactis 420 in 12 g of microcrystalline cellulose
• LU + B420: the fiber plus the same daily dose of B420 (the synbiotic combination)

Each sachet was stirred into a 250 ml bottle of commercially available fruit smoothie once per day. Participants were asked to keep their habitual diet and exercise pattern otherwise unchanged. Compliance was tracked through a check-list, returned sachet counts, and fecal quantitative PCR to confirm B420 was actually reaching the gut.¹

Participants were adults aged 18 to 65 with a body mass index between 28.0 and 34.9 and a waist-to-hip ratio of at least 0.83 for women and 0.88 for men. The exclusion list is worth noticing: diagnosed type 1 or type 2 diabetes, cardiovascular disease, recent antibiotic use, active weight-loss programs, and use of anti-obesity medications within the previous three months were all disqualifying.¹ In other words, the study population was overweight adults who were metabolically fairly healthy at baseline and who were not concurrently on any weight-loss intervention.

The pre-specified primary outcome was the relative change in total body fat mass from baseline to six months, measured by dual-energy X-ray absorptiometry (DEXA). Secondary outcomes included regional fat distribution, waist and hip circumference, body weight, food intake from five-day diaries, blood biomarkers, and fecal short-chain fatty acids.¹

What the Trial Actually Found

The findings are more interesting, and more nuanced, than a single headline figure. The results below all come from the published paper.¹

The trial defined two analysis populations before unblinding: an intention-to-treat (ITT) population of 209 participants (everyone who took at least one dose and had at least one post-baseline measurement) and a per-protocol (PP) population of 134 participants (those who completed the intervention with more than 80 percent compliance and no systemic antibiotic use). The PP population was 64 percent of the ITT population, an unusually large exclusion driven by dropouts and protocol deviations across all four arms.

A few features of these findings are worth reading carefully.

First, the reduction in body fat was concentrated in the abdominal region. The trunk fat comparison in the post-hoc factorial reached P = 0.0002, and android (central) fat reached P = 0.004.¹ Central fat is metabolically the more consequential kind, so that pattern matters.

Second, only the synbiotic arm (LU + B420) significantly increased lean body mass compared to placebo, suggesting that the fiber and the strain may combine in ways that neither ingredient does alone.¹

Third, the calorie-intake reductions were substantial. Compared to placebo, participants in the B420 and LU + B420 groups ate roughly 210 to 300 fewer kilocalories per day by month six, sustained across the intervention. That is a plausible mechanism for the fat mass difference. In the placebo group, the average participant gained about one kilogram of body weight over the six months, which is consistent with the slow, background weight gain typical of this age group in Finnish population data.¹ The B420 groups did not lose weight so much as they stopped gaining it.

Fourth, blood biomarkers moved modestly. Zonulin, a proposed marker of intestinal permeability, trended lower in the B420 groups (post-hoc factorial P = 0.063), and changes in zonulin correlated with changes in trunk fat in the LU + B420 group.¹ Fasting glucose, HbA1c, insulin, and HOMA-IR did not change, but the researchers point out that participants had normal baseline values in these markers, leaving little room to move.¹ Adverse events, safety labs, blood pressure, and heart rate were distributed evenly across groups.¹

Fifth, an independent 2020 review of the wider B420 evidence base (including in vitro, animal, and clinical work) reached the same conclusion the trial's own authors did: B420 shows promise for weight and abdominal fat management, but the finished-product and strain-level evidence in humans still rests substantially on this single six-month intervention, and further clinical studies are warranted.²

Terms to Know!

Intention-to-treat (ITT) vs. per-protocol (PP): ITT includes everyone assigned to a study group and better reflects real-world adherence. PP includes only participants who followed the study closely, which can reveal a stronger signal but may also favor people who were more likely to succeed.

Post-hoc factorial analysis: a secondary analysis performed after the main study comparison. Here, it grouped everyone who received B420 and compared them with everyone who did not. The result is useful for exploring B420's contribution, but it is not as conclusive as a result specified in advance.

What the Trial Does Not Prove

This is the section most B420 write-ups skip, so it is worth being explicit.

The pre-specified primary analysis was negative. In the ITT population, no active arm significantly outperformed placebo on the primary outcome (body fat mass change).¹ The frequently cited figures come from the smaller per-protocol subset and from a post-hoc factorial analysis. Both are legitimate ways to look at the data, and the trial's authors clearly labeled them as such. They do not, however, carry the same evidence weight as a positive primary comparison in the intention-to-treat population would.

The population studied was not people on GLP-1 medications. Semaglutide-for-obesity (Wegovy) and tirzepatide (Zepbound) were not on the consumer landscape in 2013 to 2015 in the way they are today. There is no data from this trial, or from any published B420 trial, on how the strain performs alongside these medications.

It was not a perimenopause-specific trial. About four in five participants were women, mostly in the 45 to 60 age band, so the results are informative for that demographic, but the study was not designed or powered as a menopause or perimenopause study. Hormonal transition variables were not measured or analyzed.

Participants were not people with diabetes, metabolic syndrome, or fatty liver disease. They were metabolically fairly healthy at baseline. The trial cannot support claims about diabetes prevention, glycemic control in impaired individuals, or reversal of metabolic syndrome, and the authors say so directly.¹

The finding has not been independently replicated. A systematic review published in 2024 that included the Stenman trial in a broader analysis of probiotics for weight found consistent, if modest, category-level effects across many strains and products, but did not identify an independent replication trial of B420 as a single strain conducted outside the DuPont research network.³

A trial result is not automatically a finished-product result. The Stenman trial used a specific delivery format (a sachet stirred into a specific smoothie), a specific daily dose (10¹⁰ CFU), and a specific duration (six months). Any product that departs from those parameters is trading on ingredient-level, not product-level, evidence.

How WonderBiotics Uses This Evidence

WonderBiotics uses B420 as the primary weight-management strain because the trial addresses abdominal fat, waist size, and food intake. The strain also has more human randomized-trial data than most probiotics marketed for weight, and the study framework fits the product's intended role: modest, sustained support over months rather than a rapid intervention.

WonderBiotics Probiotics for Weight Management also includes polydextrose, the same fiber used as Litesse Ultra in the LU arm of the trial. That choice is deliberate. The synbiotic combination reached statistical significance against placebo in the per-protocol population and also increased lean body mass.¹

Everything else follows from applying the evidence carefully. WonderBiotics describes B420's clinical support as strain-level and ingredient-level, not finished-product proof. The product language notes that the pre-specified primary analysis was negative and that the widely quoted figures come from per-protocol and post-hoc analyses. WonderBiotics does not claim that B420 replaces a GLP-1 medication, lifestyle change, or medical treatment because the trial tested none of those uses. Six months remains the relevant evidence window because that is how long the intervention ran.

The current formula and dose appear on the WonderBiotics Probiotics for Weight Management product page.

Reading the Numbers as They Are

B420 sits in an unusual middle position. It has more direct, DEXA-measured human trial data than the vast majority of probiotic strains sold for weight. It has considerably less evidence than a prescription weight-loss medication. It has real, biologically plausible signals for abdominal fat and appetite. It also has a pre-specified primary analysis that was not statistically significant, and a marketing story that leans on the friendlier analyses.

For someone considering a B420-containing supplement, the honest expectation is a modest shift in abdominal fat and appetite over several months, provided the starting situation resembles the trial population. That is meaningful, but smaller and more conditional than much of the marketing suggests. Weighted correctly, the evidence can still support a sound decision either way.

References

1. Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults: Randomized controlled trial. EBioMedicine. 2016;13:190-200. https://pmc.ncbi.nlm.nih.gov/articles/PMC5264483/
2. Uusitupa H-M, Rasinkangas P, Lehtinen MJ, et al. Bifidobacterium animalis subsp. lactis 420 for metabolic health: Review of the research. Nutrients. 2020;12(4):892. https://pmc.ncbi.nlm.nih.gov/articles/PMC7230722/
3. Torres S, Fabersani E, Marquez A, Gauffin-Cano P. Use of probiotics in preventing and treating excess weight and obesity: A systematic review. Obesity Science & Practice. 2024;10(3):e759. https://onlinelibrary.wiley.com/doi/10.1002/osp4.759